RBC Capital raised the firm's price target on Agilent to $155 from $153 and keeps an Outperform rating on the shares after its Q2 earnings beat. Agilent exceeded Street expectations, flagging strength in several product cycles with more to come, the analyst tells investors in a research note. The firm notes that its constructive view on Agilent is anchored by building product cycle momentum across key instrument platforms and exposure to drug manufacturing, RBC added.
